Unraveling the relationship between the DRPs with PANNS and extrapyramidal symptoms in schizophrenia: Implications for antipsychotic therapy
Abstract
Schizophrenia is a severe and chronic mental disorder that requires long-term antipsychotic therapy. However, the use of these medications is often accompanied by drug-related problems (DRPs), which affect the effectiveness of treatment and increase the risk of health complications. Objective: This study aims to evaluate the relationship between DRPs and therapy outcomes in schizophrenia patients at Syamrabu Bangkalan Hospital. Methods: A cross-sectional design with a retrospective method was used in this study. The sample was selected through purposive sampling from patients diagnosed with mental disorders who were using antipsychotic drugs. The PANSS scores and the frequency of extrapyramidal events were assessed to evaluate therapy outcomes. The data analysis was conducted using statistical correlation tests. Results: Among the 110 patients studied, 200 cases of DRPs were found, with drug interactions being the most common (42.5%). Correlation analysis showed a significant relationship between the number of drugs consumed and the number of DRPs (p=0.000, r=0.352). However, no significant association was found between the number of DRPs and patient therapeutic outcomes (p=0.340, r=-0.076). Combining atypical and typical antipsychotics proved more effective in reducing PANSS scores and demonstrating a lower risk of extrapyramidal side effects compared to monotherapy. Conclusion: An increase in the number of medications taken by a schizophrenia patient correlates with a higher incidence of DRPs. Therefore, close monitoring and pharmaceutical interventions are needed to optimize therapy and reduce the risk of side effects and complications.
Keywords
References
Abouzaid, S., Tian, H., Zhou, H., Kahler, K. H., Harris, M., & Kim, E. (2014a). Economic burden associated with extrapyramidal symptoms in a medicaid population with schizophrenia. Community Mental Health Journal, 50(1), 51–58. https://doi.org/10.1007/s10597-012-9561-7
Abouzaid, S., Tian, H., Zhou, H., Kahler, K. H., Harris, M., & Kim, E. (2014b). Economic burden associated with extrapyramidal symptoms in a medicaid population with schizophrenia. Community Mental Health Journal, 50(1), 51–58. https://doi.org/10.1007/s10597-012-9561-7
Alshaikhmubarak, F. Q., Keers, R. N., & Lewis, P. J. (2023). Potential Risk Factors of Drug-Related Problems in Hospital-Based Mental Health Units: A Systematic Review. In Drug Safety (Vol. 46, Issue 1, pp. 19–37). Adis. https://doi.org/10.1007/s40264-022-01249-1
Arozal, W., Wijaya, D., Soetikno, V., Amir, N., & Setiabudy, R. (2019). Treatment patterns of antipsychotics and clinical features for treating patients with schizophrenia at the teaching hospital in Jakarta, Indonesia. Journal of Applied Pharmaceutical Science, 9(2), 57–63. https://doi.org/10.7324/JAPS.2019.90208
Aryastami, N. K., & Mubasyiroh, R. (2023). Optimal utilization of maternal health services in Indonesia: a cross-sectional study of Riskesdas 2018. BMJ Open, 13(9). https://doi.org/10.1136/bmjopen-2022-067959
Cahaya, N., Kristina, S. A., Widayanti, A. W., & Green, J. A. (2024). Pharmacist-led Si-care (schizophrenia care) model to improve medication adherence and symptom management in schizophrenia. Exploratory Research in Clinical and Social Pharmacy, 16. https://doi.org/10.1016/j.rcsop.2024.100544
Indriani, A., Ardiningrum, W., & Febrianti, Y. (2020). Studi Penggunaan Kombinasi Antipsikotik pada Pasien Skizofrenia di Rumah Sakit Yogyakarta. Majalah Farmasetika., 4. https://doi.org/10.24198/mfarmasetika.v4i0.25882
Kluzek, S., Dean, B., & Wartolowska, K. A. (2022). Patient-reported outcome measures (PROMs) as proof of treatment efficacy. In BMJ Evidence-Based Medicine (Vol. 27, Issue 3, pp. 153–155). BMJ Publishing Group. https://doi.org/10.1136/bmjebm-2020-111573
Launders, N., Dotsikas, K., Marston, L., Price, G., Osborn, D. P. J., & Hayes, J. F. (2022a). The impact of comorbid severe mental illness and common chronic physical health conditions on hospitalisation: A systematic review and meta-analysis. In PLoS ONE (Vol. 17, Issue 8, August). Public Library of Science. https://doi.org/10.1371/journal.pone.0272498
Launders, N., Dotsikas, K., Marston, L., Price, G., Osborn, D. P. J., & Hayes, J. F. (2022b). The impact of comorbid severe mental illness and common chronic physical health conditions on hospitalisation: A systematic review and meta-analysis. In PLoS ONE (Vol. 17, Issue 8, August). Public Library of Science. https://doi.org/10.1371/journal.pone.0272498
Marvin, V., Ward, E., Jubraj, B., Bower, M., & Bovill, I. (2018). Improving Pharmacists' Targeting of Patients for Medication Review and Deprescribing. Pharmacy, 6(2), 32. https://doi.org/10.3390/pharmacy6020032
Mateti, U., Lalwani, T., Nagappa, A., Bhandary, P., Verupaksha, D., & Balkrishnan, R. (2015). Assessment of drug-related problems in depressive patients. Perspectives in Clinical Research, 6(1), 58. https://doi.org/10.4103/2229-3485.148820
Mosolov, S. N., & Yaltonskaya, P. A. (2022). Primary and Secondary Negative Symptoms in Schizophrenia. In Frontiers in Psychiatry (Vol. 12). Frontiers Media S.A. https://doi.org/10.3389/fpsyt.2021.766692
Nasim, R., Nawaz, S., & Nasim, M. T. (2025). The Effects of Antipsychotic Drugs and Non-Pharmacological Therapies on Schizophrenia. Targets, 3(1), 10. https://doi.org/10.3390/targets3010010
Ng, R., El-Den, S., Stewart, V., Collins, J. C., Roennfeldt, H., McMillan, S. S., Wheeler, A. J., & O’Reilly, C. L. (2022). Pharmacist-led interventions for people living with severe and persistent mental illness: A systematic review. In Australian and New Zealand Journal of Psychiatry (Vol. 56, Issue 9, pp. 1080–1103). SAGE Publications Inc. https://doi.org/10.1177/00048674211048410
Rubio, J. M., Taipale, H., Tanskanen, A., Correll, C. U., Kane, J. M., & Tiihonen, J. (2021). Long-term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study. Schizophrenia Bulletin, 47(6), 1611–1620. https://doi.org/10.1093/schbul/sbab063
Sampogna, G., Di Vincenzo, M., Giuliani, L., Menculini, G., Mancuso, E., Arsenio, E., Cipolla, S., Della Rocca, B., Martiadis, V., Signorelli, M. S., & Fiorillo, A. (2023). A Systematic Review on the Effectiveness of Antipsychotic Drugs on the Quality of Life of Patients with Schizophrenia. In Brain Sciences (Vol. 13, Issue 11). Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/brainsci13111577
Solmi, M., Murru, A., Pacchiarotti, I., Undurraga, J., Veronese, N., Fornaro, M., Stubbs, B., Monaco, F., Vieta, E., Vseeman, M., Correll, C. U., & Carvalho, A. F. (2017). Safety, tolerability, and risks associated with first- and second-generation antipsychotics: A state-of-the-art clinical review. In Therapeutics and Clinical Risk Management (Vol. 13, pp. 757–777). Dove Medical Press Ltd. https://doi.org/10.2147/TCRM.S117321
Tadesse, Y. B., Sendekie, A. K., Mekonnen, B. A., Denberu, F. G., & Kassaw, A. T. (2023). Pharmacists’ Medication Counseling Practices and Knowledge and Satisfaction of Patients With an Outpatient Hospital Pharmacy Service. Inquiry (United States), 60. https://doi.org/10.1177/00469580231219457
Tharanon, V., Putthipokin, K., & Sakthong, P. (2022). Drug-related problems identified during pharmaceutical care interventions in an intensive care unit at a tertiary university hospital. SAGE Open Medicine, 10. https://doi.org/10.1177/20503121221090881
Wien, K., Reißner, P., Hefner, G., Thern, J., & Borgwardt, S. (2024). Prevalence and solving strategies of drug-related problems in adult psychiatric inpatients - a systematic review. In Frontiers in Psychiatry (Vol. 15). Frontiers Media SA. https://doi.org/10.3389/fpsyt.2024.1460098
Article Statistic
Abstract view : 259 timesPDF (Bahasa Indonesia) views : 193 times
Dimensions Metrics
How To Cite This :
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Email this article 
